Description

Rapimig (zolmitriptan) dispersible tablets 2,5 mg. №2

Ingredients:

Each dispersible tablet contains 2.5 mg of zolmitriptan.

Dosage:

The recommended dosage is one tablet at the onset of a migraine headache. Do not exceed more than 10 mg in a 24-hour period.

Indications:

Rapimig dispersible tablets are indicated for the acute treatment of migraine attacks with or without aura.

Contraindications:

Do not use Rapimig if you have uncontrolled hypertension, ischemic heart disease, or have taken ergotamine derivatives within the last 24 hours.

Directions:

Place the tablet on the tongue, where it will disintegrate in saliva. Swallow the tablet with saliva. No water is needed.

Scientific Evidence:

Zolmitriptan, the active ingredient in Rapimig, is a selective serotonin receptor agonist that works by constricting blood vessels in the brain, thereby reducing the swelling associated with migraines. Clinical studies have shown that zolmitriptan is effective in relieving migraine symptoms, including pain, nausea, and sensitivity to light and sound.

Research published in the journal Headache demonstrated that zolmitriptan dispersible tablets provided rapid and sustained relief of migraine pain compared to a placebo, with a significant number of patients experiencing pain relief within 2 hours of taking the medication.

Additional Information:

• Rapimig dispersible tablets offer a convenient and fast-acting option for migraine relief.
• Avoid driving or operating machinery after taking Rapimig, as it may cause dizziness or drowsiness.
• If you have a history of heart problems or are pregnant or breastfeeding, consult your healthcare provider before using Rapimig.